title: Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site.
authors.affiliation: Ashford Cancer Centre, South Australia, Australia.
authors.forename: F X
authors.initials: FX
authors.lastname: Parnis
authors.forename: I N
authors.initials: IN
authors.lastname: Olver
authors.forename: D
authors.initials: D
authors.lastname: Kotasek
authors.forename: J
authors.initials: J
authors.lastname: Norman
authors.forename: A
authors.initials: A
authors.lastname: Taylor
authors.forename: J
authors.initials: J
authors.lastname: Russell
authors.forename: K
authors.initials: K
authors.lastname: Patterson
authors.forename: D
authors.initials: D
authors.lastname: Keefe
authors.forename: T
authors.initials: T
authors.lastname: Marafioti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil